Revuforj/Revumenib (SNDX-5613) Post-Transplant Maintenance (Menin Inhibitor)

May 21, 2026 — Syndax Pharmaceuticals (Nasdaq: SNDX) announced that four abstracts on Revuforj® (revumenib), its oral first-in-class menin inhibitor, were accepted for presentation at the ASCO Annual Meeting (May 29–June 2, 2026; Chicago). The program includes an oral presentation on revumenib used as post–hematopoietic stem cell transplantation (HSCT) maintenance in 21 adult and pediatric patients with KMT2A-rearranged, NPM1-mutated, or NUP98-rearranged acute leukemia, reporting overall survival and relapse rate and comparing outcomes with a historical pre-revumenib cohort. A pharmacokinetics poster will describe dosing considerations, including administration with gastric acid–reducing agents, low-fat meals, and dose-adjustment guidance with strong CYP3A4 inhibitors. Two additional “trial in progress” posters outline Phase 3 studies in newly diagnosed AML: revumenib plus venetoclax/azacitidine in patients ineligible for intensive chemotherapy (EVOLVE-2) and revumenib plus intensive chemotherapy in NPM1-mutated AML (REVEAL-ND NPM1). Clinically, the presentations aim to support expanded use and optimized dosing of revumenib and to advance pivotal development in frontline AML.